Avery Therapeutics’ mission is to advance tissue-engineered therapeutics to treat diseases and injuries to human muscle. Avery’s first product, MyCardia™ is a tissue engineered graft for treatment of chronic heart failure. Chronic heart failure is a critical need worldwide with 26M people diagnosed and no therapies that effectively reverse the disease process or restore function to the heart long term. MyCardia™ has the potential to be the first available therapy that regenerates tissue and restores the heart to effective function for a high quality of life. MyCardia™ is a three part product comprised of a bio- absorbable scaffold seeded with fibroblasts and induced pluripotent stem cell derived cardiomyocytes. Each cell type provides a unique therapeutic element and taken together synergistically improves the heart. MyCardia™ mimics key molecular and cellular attributes of cardiac tissue and behaves like cardiac tissue. MyCardia™ beats spontaneously and synchronously and electrically couples with the heart. We have data showing that MyCardia™ improves cardiac function in pre-clinical models of heart failure and results in generation of new blood vessels and heart muscle. Of additional importance is that pre-clinical studies with MyCardia™ have shown improvements in diastolic function, which has the potential to be immensely impactful in the heart failure population since there are no existing therapies to treat diastolic dysfunction.